Irbepress

Irbesartan, the active ingredient in Irbepress, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and helps preserve kidney function in patients with diabetes‑related kidney disease, acting by blocking the effects of angiotensin II.

GNH USA supplies Irbepress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is available for export to multiple regions, ensuring consistent quality and reliable supply chains for healthcare providers.

Irbesartan is an angiotensin II receptor blocker used in cardiovascular and renal disease management.

- Hypertension: reduces systolic and diastolic blood pressure to achieve target levels. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes. - Proteinuric kidney disease: decreases urinary protein excretion and protects renal function.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Severe hypotension: markedly low blood pressure causing fainting or shock. - Acute renal failure: sudden loss of kidney function, indicated by rising creatinine levels.

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR periodically. - Serum potassium: monitor for hyperkalaemia, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: avoid use as safety in pregnancy is not established. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal impairment. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive potassium rise and kidney injury. - Potassium‑sparing diuretics (e.g., spironolactone): heightens risk of hyperkalaemia.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Lithium: increased lithium levels can lead to toxicity. - NSAIDs: may reduce antihypertensive efficacy and affect renal function.